Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Cash & Equivalents (2017 - 2025)

Cue Biopharma's Cash & Equivalents history spans 9 years, with the latest figure at $11.7 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents changed N/A year-over-year to $11.7 million; the TTM value through Sep 2025 reached $11.7 million, changed N/A, while the annual FY2024 figure was $22.5 million, 53.71% down from the prior year.
  • Cash & Equivalents for Q3 2025 was $11.7 million at Cue Biopharma, down from $22.5 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $73.9 million in Q2 2021 and bottomed at $11.7 million in Q3 2025.
  • The 5-year median for Cash & Equivalents is $50.1 million (2022), against an average of $45.2 million.
  • The largest annual shift saw Cash & Equivalents dropped 1.14% in 2022 before it crashed 53.71% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $52.2 million in 2021, then dropped by 1.14% to $51.6 million in 2022, then decreased by 6.01% to $48.5 million in 2023, then plummeted by 53.71% to $22.5 million in 2024, then crashed by 47.9% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Cash & Equivalents are $11.7 million (Q3 2025), $22.5 million (Q4 2024), and $41.0 million (Q1 2024).